메뉴 건너뛰기




Volumn 11, Issue 11, 2011, Pages 1671-1676

Role of bacillus Calmette–Guérin in the treatment of advanced melanoma

Author keywords

adjuvant therapy; bacillus Calmette Gu rin vaccine; clinical trials; immunotherapy; malignant melanoma; Toll like receptors

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

EID: 84857067056     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.163     Document Type: Article
Times cited : (44)

References (48)
  • 2
    • 77950366767 scopus 로고    scopus 로고
    • BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control
    • Merle CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev. Vaccines 9 (2), 209 –222 (2010).
    • (2010) Expert Rev. Vaccines , vol.9 , Issue.2 , pp. 209-222
    • Merle, C.S.1    Cunha, S.S.2    Rodrigues, L.C.3
  • 3
    • 0037323336 scopus 로고    scopus 로고
    • The effect of bacille Calmette–Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS
    • Paolillo A, Buzzi MG, Giugni E et al. The effect of bacille Calmette–Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS. J. Neurol. 250 (2), 247 –248 (2003).
    • (2003) J. Neurol. , vol.250 , Issue.2 , pp. 247-248
    • Paolillo, A.1    Buzzi, M.G.2    Giugni, E.3
  • 4
    • 79960677601 scopus 로고    scopus 로고
    • Fact and fiction in tuberculosis vaccine research: 10 years later
    • Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect. Dis. 11 (8), 633 –640 (2011).
    • (2011) Lancet Infect. Dis. , vol.11 , Issue.8 , pp. 633-640
    • Kaufmann, S.H.1
  • 5
    • 75149136162 scopus 로고    scopus 로고
    • Bacillus Calmette–Guérin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy
    • Yuk JM, Shin DM, Song KS et al. Bacillus Calmette–Guérin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. Autophagy 6 (1), 46 –60 (2010).
    • (2010) Autophagy , vol.6 , Issue.1 , pp. 46-60
    • Yuk, J.M.1    Shin, D.M.2    Song, K.S.3
  • 6
    • 78751641748 scopus 로고    scopus 로고
    • Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer
    • Weizer AZ, Tallman C, Montgomery JS. Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. World J. Urol. 29 (1), 59 –71 (2010).
    • (2010) World J. Urol. , vol.29 , Issue.1 , pp. 59-71
    • Weizer, A.Z.1    Tallman, C.2    Montgomery, J.S.3
  • 7
    • 0017116422 scopus 로고
    • Intralesional immunotherapy of melanoma with BCG
    • Rosenberg SA, Rapp HJ. Intralesional immunotherapy of melanoma with BCG. Med. Clin. North Am. 60 (3), 419 –430 (1976).
    • (1976) Med. Clin. North Am. , vol.60 , Issue.3 , pp. 419-430
    • Rosenberg, S.A.1    Rapp, H.J.2
  • 8
    • 0026032351 scopus 로고
    • Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis
    • de Boer EC, de Jong WH, van der Meijden AP et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol. Res. 19 (1), 45 –50 (1991).
    • (1991) Urol. Res. , vol.19 , Issue.1 , pp. 45-50
    • de Boer, E.C.1    de Jong, W.H.2    van der, M.A.3
  • 9
    • 33947694370 scopus 로고    scopus 로고
    • TLR signaling
    • Kawai T, Akira S. TLR signaling. Semin. Immunol. 19 (1), 24 –32 (2007).
    • (2007) Semin. Immunol. , vol.19 , Issue.1 , pp. 24-32
    • Kawai, T.1    Akira, S.2
  • 10
    • 2442710545 scopus 로고    scopus 로고
    • Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette–Guérin-induced antitumor activity
    • Ludwig AT, Moore JM, Luo Y et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette–Guérin-induced antitumor activity. Cancer Res. 64 (10), 3386 –3390 (2004).
    • (2004) Cancer Res. , vol.64 , Issue.10 , pp. 3386-3390
    • Ludwig, A.T.1    Moore, J.M.2    Luo, Y.3
  • 11
    • 0036499079 scopus 로고    scopus 로고
    • Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon α-2b for high-risk melanoma patients using intergroup clinical trial data
    • Kilbridge KL, Cole BF, Kirkwood JM et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon α-2b for high-risk melanoma patients using intergroup clinical trial data. J. Clin. Oncol. 20 (5), 1311 –1318 (2002).
    • (2002) J. Clin. Oncol. , vol.20 , Issue.5 , pp. 1311-1318
    • Kilbridge, K.L.1    Cole, B.F.2    Kirkwood, J.M.3
  • 12
    • 0141817861 scopus 로고    scopus 로고
    • Impact of vaccinations and infectious diseases on the risk of melanoma – evaluation of an EORTC case–control study
    • Krone B, Kolmel KF, Grange JM et al. Impact of vaccinations and infectious diseases on the risk of melanoma – evaluation of an EORTC case–control study. Eur. J. Cancer 39 (16), 2372 –2378 (2003).
    • (2003) Eur. J. Cancer , vol.39 , Issue.16 , pp. 2372-2378
    • Krone, B.1    Kolmel, K.F.2    Grange, J.M.3
  • 13
    • 0026778718 scopus 로고
    • Febrile infections and malignant melanoma: results of a case–control study
    • Kolmel KF, Gefeller O, Haferkamp B. Febrile infections and malignant melanoma: results of a case–control study. Melanoma Res. 2 (3), 207 –211 (1992).
    • (1992) Melanoma Res. , vol.2 , Issue.3 , pp. 207-211
    • Kolmel, K.F.1    Gefeller, O.2    Haferkamp, B.3
  • 14
    • 19944383121 scopus 로고    scopus 로고
    • Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients
    • Kolmel KF, Grange JM, Krone B et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur. J. Cancer 41 (1), 118 –125 (2005).
    • (2005) Eur. J. Cancer , vol.41 , Issue.1 , pp. 118-125
    • Kolmel, K.F.1    Grange, J.M.2    Krone, B.3
  • 15
    • 18544377660 scopus 로고    scopus 로고
    • Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study
    • Pfahlberg A, Kolmel KF, Grange JM et al. Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. J. Invest. Dermatol. 119 (3), 570 –575 (2002).
    • (2002) J. Invest. Dermatol. , vol.119 , Issue.3 , pp. 570-575
    • Pfahlberg, A.1    Kolmel, K.F.2    Grange, J.M.3
  • 16
    • 1842582038 scopus 로고    scopus 로고
    • Mature results of a Phase III randomized trial of bacillus Calmette–Guérin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer stage I-III melanoma (E1673): a trial of the Eastern Oncology Group
    • Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a Phase III randomized trial of bacillus Calmette–Guérin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 100 (8), 1692 –1698 (2004).
    • (2004) Cancer , vol.100 , Issue.8 , pp. 1692-1698
    • Agarwala, S.S.1    Neuberg, D.2    Park, Y.3    Kirkwood, J.M.4
  • 17
    • 0025858804 scopus 로고
    • Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a Phase III study by the National Cancer Institute of Canada Clinical Trials Group
    • Quirt IC, Shelley WE, Pater JL et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a Phase III study by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 9 (5), 729 –735 (1991).
    • (1991) J. Clin. Oncol. , vol.9 , Issue.5 , pp. 729-735
    • Quirt, I.C.1    Shelley, W.E.2    Pater, J.L.3
  • 18
    • 0024556019 scopus 로고
    • The significance of conversion of skin reactivity to efficacy of bacillus Calmette–Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients
    • Cascinelli N, Rumke P, MacKie R, Morabito A, Bufalino R. The significance of conversion of skin reactivity to efficacy of bacillus Calmette–Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol. Immunother. 28 (4), 282 –286 (1989).
    • (1989) Cancer Immunol. Immunother. , vol.28 , Issue.4 , pp. 282-286
    • Cascinelli, N.1    Rumke, P.2    MacKie, R.3    Morabito, A.4    Bufalino, R.5
  • 19
    • 34548249596 scopus 로고    scopus 로고
    • An international, randomized, Phase III Trial of bacillus Calmette–Guérin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma to regional or distant sites
    • Morton DL, Mozzillo N, Thompson JF et al. An international, randomized, Phase III Trial of bacillus Calmette–Guérin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma to regional or distant sites. J. Clin. Oncol. 2007 ASCO Ann. Meeting Proc. 25 (18 Suppl.), 8508 (2007).
    • (2007) J. Clin. Oncol. 2007 ASCO Ann. Meeting Proc. , vol.25 , pp. 8508
    • Morton, D.L.1    Mozzillo, N.2    Thompson, J.F.3
  • 20
    • 3042666881 scopus 로고    scopus 로고
    • An evidence-based staging system for cutaneous melanoma
    • quiz 182–184 (2004).
    • Balch CM, Soong SJ, Atkins MB et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J. Clin. 54 (3), 131 –149; quiz 182–184 (2004).
    • CA Cancer J. Clin. , vol.54 , Issue.3 , pp. 131-149
    • Balch, C.M.1    Soong, S.J.2    Atkins, M.B.3
  • 21
    • 0017079017 scopus 로고
    • Metastatic potential of metastases
    • Roth JA, Silverstein MJ, Morton DL. Metastatic potential of metastases. Surgery 79 (6), 669 –673 (1976).
    • (1976) Surgery , vol.79 , Issue.6 , pp. 669-673
    • Roth, J.A.1    Silverstein, M.J.2    Morton, D.L.3
  • 22
    • 33745635043 scopus 로고    scopus 로고
    • The stem-cell niche as an entity of action
    • Scadden DT. The stem-cell niche as an entity of action. Nature 441 (7097), 1075 –1079 (2006).
    • (2006) Nature , vol.441 , Issue.7097 , pp. 1075-1079
    • Scadden, D.T.1
  • 23
    • 33947504062 scopus 로고    scopus 로고
    • Molecular mechanisms and therapeutic reversal of immune suppression in cancer
    • Gabrilovich DI. Molecular mechanisms and therapeutic reversal of immune suppression in cancer. Curr. Cancer Drug Targets 7 (1), 1 (2007).
    • (2007) Curr. Cancer Drug Targets , vol.7 , Issue.1 , pp. 1
    • Gabrilovich, D.I.1
  • 24
    • 79959684874 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation
    • Mauti LA, Le Bitoux MA, Baumer K et al. Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J. Clin. Invest. 121 (7), 2794 –2807 (2011).
    • (2011) J. Clin. Invest. , vol.121 , Issue.7 , pp. 2794-2807
    • Mauti, L.A.1    Le Bitoux, M.A.2    Baumer, K.3
  • 25
    • 79960003585 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
    • Raychaudhuri B, Rayman P, Ireland J et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 13 (6), 591 –599 (2011).
    • (2011) Neuro Oncol. , vol.13 , Issue.6 , pp. 591-599
    • Raychaudhuri, B.1    Rayman, P.2    Ireland, J.3
  • 26
    • 79959966013 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer
    • Goedegebuure P, Mitchem JB, Porembka MR et al. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr. Cancer Drug Targets 11 (6), 734 –751 (2011).
    • (2011) Curr. Cancer Drug Targets , vol.11 , Issue.6 , pp. 734-751
    • Goedegebuure, P.1    Mitchem, J.B.2    Porembka, M.R.3
  • 27
    • 33746040164 scopus 로고    scopus 로고
    • The inflammatory tumor microenvironment and its impact on cancer development
    • de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib. Microbiol. 13, 118 –137 (2006).
    • (2006) Contrib. Microbiol. , vol.13 , pp. 118-137
    • de Visser, K.E.1    Coussens, L.M.2
  • 28
    • 79960835345 scopus 로고    scopus 로고
    • High FOXP3+ regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer
    • H.E., Lee, D.J., Park, W.H., Kim, H.H., Kim, H.S., Lee, High FOXP3+ regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer, Br. J. Cancer, (2011), 105, 3, 413-419
    • (2011) Br. J. Cancer , vol.105 , Issue.3 , pp. 413-419
    • Lee, H.E.1    Park, D.J.2    Kim, W.H.3    Kim, H.H.4    Lee, H.S.5
  • 29
    • 85027940310 scopus 로고    scopus 로고
    • CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes
    • Liu F, Lang R, Zhao J et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res. Treat. 130 (2), 645 –655 (2011).
    • (2011) Breast Cancer Res. Treat. , vol.130 , Issue.2 , pp. 645-655
    • Liu, F.1    Lang, R.2    Zhao, J.3
  • 30
    • 38949200291 scopus 로고    scopus 로고
    • Effect of melanoma on immune function in the regional lymph node basin
    • Negin B, Panka D, Wang W et al. Effect of melanoma on immune function in the regional lymph node basin. Clin. Cancer Res. 14 (3), 654 –659 (2008).
    • (2008) Clin. Cancer Res. , vol.14 , Issue.3 , pp. 654-659
    • Negin, B.1    Panka, D.2    Wang, W.3
  • 31
    • 0030030347 scopus 로고    scopus 로고
    • Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684
    • Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14 (1), 7 –17 (1996).
    • (1996) J. Clin. Oncol. , vol.14 , Issue.1 , pp. 7-17
    • Kirkwood, J.M.1    Strawderman, M.H.2    Ernstoff, M.S.3    Smith, T.J.4    Borden, E.C.5    Blum, R.H.6
  • 32
    • 0034088027 scopus 로고    scopus 로고
    • High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190
    • Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18 (12), 2444 –2458 (2000).
    • (2000) J. Clin. Oncol. , vol.18 , Issue.12 , pp. 2444-2458
    • Kirkwood, J.M.1    Ibrahim, J.G.2    Sondak, V.K.3
  • 33
    • 0035339880 scopus 로고    scopus 로고
    • High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801
    • Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19 (9), 2370 –2380 (2001).
    • (2001) J. Clin. Oncol. , vol.19 , Issue.9 , pp. 2370-2380
    • Kirkwood, J.M.1    Ibrahim, J.G.2    Sosman, J.A.3
  • 34
    • 7144228601 scopus 로고    scopus 로고
    • Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma
    • Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351 (9120), 1905 –1910 (1998).
    • (1998) Lancet , vol.351 , Issue.9120 , pp. 1905-1910
    • Grob, J.J.1    Dreno, B.2    de la Salmoniere, P.3
  • 35
    • 7144264391 scopus 로고    scopus 로고
    • Adjuvant interferon α-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group
    • Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon α-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J. Clin. Oncol. 16 (4), 1425 –1429 (1998).
    • (1998) J. Clin. Oncol. , vol.16 , Issue.4 , pp. 1425-1429
    • Pehamberger, H.1    Soyer, H.P.2    Steiner, A.3
  • 36
    • 3242686449 scopus 로고    scopus 로고
    • Adjuvant interferon in high-risk melanoma: the AIM HIGH Study – United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon α-2a in high-risk resected malignant melanoma
    • Hancock BW, Wheatley K, Harris S et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study – United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon α-2a in high-risk resected malignant melanoma. J. Clin. Oncol. 22 (1), 53 –61 (2004).
    • (2004) J. Clin. Oncol. , vol.22 , Issue.1 , pp. 53-61
    • Hancock, B.W.1    Wheatley, K.2    Harris, S.3
  • 37
    • 0035805053 scopus 로고    scopus 로고
    • Adjuvant interferon α 2b in high risk melanoma – the Scottish study
    • Cameron DA, Cornbleet MC, Mackie RM et al. Adjuvant interferon α 2b in high risk melanoma – the Scottish study. Br. J. Cancer 84 (9), 1146 –1149 (2001).
    • (2001) Br. J. Cancer , vol.84 , Issue.9 , pp. 1146-1149
    • Cameron, D.A.1    Cornbleet, M.C.2    Mackie, R.M.3
  • 38
    • 0035883950 scopus 로고    scopus 로고
    • Effect of long-term adjuvant therapy with interferon α-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial
    • Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon α-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358 (9285), 866 –869 (2001).
    • (2001) Lancet , vol.358 , Issue.9285 , pp. 866-869
    • Cascinelli, N.1    Belli, F.2    MacKie, R.M.3    Santinami, M.4    Bufalino, R.5    Morabito, A.6
  • 39
    • 44849131339 scopus 로고    scopus 로고
    • Adjuvant low-dose interferon {α}2a with or without dacarbazine compared with surgery alone: a prospective-randomized Phase III DeCOG trial in melanoma patients with regional lymph node metastasis
    • Garbe C, Radny P, Linse R et al. Adjuvant low-dose interferon {α}2a with or without dacarbazine compared with surgery alone: a prospective-randomized Phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann. Oncol. 19 (6), 1195 –1201 (2008).
    • (2008) Ann. Oncol. , vol.19 , Issue.6 , pp. 1195-1201
    • Garbe, C.1    Radny, P.2    Linse, R.3
  • 40
    • 25844465690 scopus 로고    scopus 로고
    • Post-surgery adjuvant therapy with intermediate doses of interferon α 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
    • Eggermont AM, Suciu S, MacKie R et al. Post-surgery adjuvant therapy with intermediate doses of interferon α 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366 (9492), 1189 –1196 (2005).
    • (2005) Lancet , vol.366 , Issue.9492 , pp. 1189-1196
    • Eggermont, A.M.1    Suciu, S.2    MacKie, R.3
  • 41
    • 3242734089 scopus 로고    scopus 로고
    • Tolerability of adjuvant high-dose interferon α-2b: 1 month versus 1 year – a Hellenic Cooperative Oncology Group study
    • Gogas H, Bafaloukos D, Ioannovich J et al. Tolerability of adjuvant high-dose interferon α-2b: 1 month versus 1 year – a Hellenic Cooperative Oncology Group study. Anticancer Res. 24 (3b), 1947 –1952 (2004).
    • (2004) Anticancer Res. , vol.24 , Issue.3b , pp. 1947-1952
    • Gogas, H.1    Bafaloukos, D.2    Ioannovich, J.3
  • 42
    • 46749103710 scopus 로고    scopus 로고
    • Adjuvant therapy with pegylated interferon α-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial
    • Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon α-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial. Lancet 372 (9633), 117 –126 (2008).
    • (2008) Lancet , vol.372 , Issue.9633 , pp. 117-126
    • Eggermont, A.M.1    Suciu, S.2    Santinami, M.3
  • 43
    • 0025228650 scopus 로고
    • Thoracotomy for metastatic malignant melanoma of the lung
    • Karp NS, Boyd A, DePan HJ, Harris MN, Roses DF. Thoracotomy for metastatic malignant melanoma of the lung. Surgery 107 (3), 256 –261 (1990).
    • (1990) Surgery , vol.107 , Issue.3 , pp. 256-261
    • Karp, N.S.1    Boyd, A.2    DePan, H.J.3    Harris, M.N.4    Roses, D.F.5
  • 45
    • 0025836919 scopus 로고
    • Role of surgical intervention in the management of intestinal metastases from malignant melanoma
    • Branum GD, Seigler HF. Role of surgical intervention in the management of intestinal metastases from malignant melanoma. Am. J. Surg. 162 (5), 428 –431 (1991).
    • (1991) Am. J. Surg. , vol.162 , Issue.5 , pp. 428-431
    • Branum, G.D.1    Seigler, H.F.2
  • 47
    • 0036896972 scopus 로고    scopus 로고
    • Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine
    • Hsueh EC, Essner R, Foshag LJ et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol. 20 (23), 4549 –4554 (2002).
    • (2002) J. Clin. Oncol. , vol.20 , Issue.23 , pp. 4549-4554
    • Hsueh, E.C.1    Essner, R.2    Foshag, L.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.